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In conclusion, we suggest that TB should be
excluded in any febrile patient with hypercalcemia
especially in countries where tuberculosis is endemic.
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Anti-Rh17 (Anti-Hr0): a rare Diagnostic and Management Problem
N. Salamat, F. A. Bhatti, A. Hussain, Ziaullah
Armed Forces Institute of Transfusion, Rawalpindi.

Introduction
Of all blood group systems, anti Rh antibodies are
the commonest cause of haemolytic disease of the newborn
(HDN) and its diagnosis and management plan is well
established. Also immunization with 'D' antigen can be
effectively prevented by prophylactic use of anti-D
Immunoglobulin. Therefore its prevalence has declined but
now less common alloantibodies are frequently encountered
posing different management problems. Anti Rh17 is also a
rare alloantibody1 produced after immune stimulus, by
individuals who lack C/c and E/e antigens of Rh blood
group on their red cells. This rare blood group is designated
as D- - and was first described by Race and Sanger2 in 1950.
We report diagnosis and management of a pregnant lady
with anaemia, mitral valve disease and anti Rh17
alloantibody who required blood for operation and her baby
suffered from hydrops foetalis.

Case Report
A 35 years old lady, (gravida 4, term 2, premature
0, abortion 0, live birth 1) diagnosed case of moderately
severe mitral valve stenosis was admitted in Armed Forces
Institute of Cardiology (AFIC) with amenorrhoea of 7
months duration, shortness of breath NYHA III/IV and
palpitations for 5 months. Her first pregnancy ended in
intrapartum death in 1998 at full term. Next year a full term
healthy boy was delivered by Caesarean-section and patient
was transfused one unit of whole blood in post partum
period. The child did not have a history of neonatal jaundice
or anaemia. In 2001 her next pregnancy ended with
intrauterine death at 34th week of gestation and dead
hydropic fetus was delivered by Caesarean-section. Fourth
pregnancy started in Oct 2002 and she became
progressively dyspnoeic, had palpitations and was
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hospitalized. Her physical examination revealed
tachycardia with regular rhythm, BP of 110/70 mmHg,
respiratory rate 24/min and pitting edema of both feet.
Grade II diastolic murmur was audible on precordium.
Abdominal fundal height was 38 weeks while gestational
age by dates was 34 weeks. Her haemoglobin level was 4.3
g/dl, with red cells showing microcytosis and hypochromia.
Echocardiography showed moderately severe mitral
stenosis and ejection fraction of 65%. Rest all of the
investigations were within normal limits. Ultrasound of
abdomen revealed single alive foetus with ascites and
pleural effusion, suggesting hydrops foetalis, whereas
placenta was large and fundal and she had developed
polyhydramnios. She was prescribed 1/V injection of Iron
sucrose (Venofer) 20 mg/day for 6 days and also received
oral iron/folic acid 200 mg, Spironolactone 40 mg, and
Digoxin 0.25 mg every day. Clotted blood sample of the
patient was sent to our centre for grouping and cross
matching. The serological test3 and results following this
request are summarized in Table 1. Interpretation of these
results was that patient is having IgG type, alloantibody,
directed against some high frequency (public) red cell
antigen. To determine the specificity of antibody and to find
compatible blood, rare red cells panels and antisera were
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Table 1. Initial serological tests.
S. No

Test

Reagent

1.

ABO Grouping

2.

Rh 'D' Grouping

Method

(Monclonal Bio Tech Labs

Result

Tube, IS

BEE

Tube, IS

D Positive

Ltd,UK)
Monoclonal IgM + IgG Blended,
Biotech Labs Ltd, UK)
3.

Cross match with random
donors

Lorne UK, LISS, AHG

Tube LISS IAT

Incompatible with all
donors

4

Antibody screening with 3 Cell panel

Maxi screen cells Lorne, UK

LISS-Additive IAT in Tube

1+ at 370C with all cells
and 4+ agglutination with
all three cells with IAT

5

Auto control

-

RT, 37 0C, IAT

Negative

6

Direct antiglobulin test

AHG, Lorne UK

Tube

Negative

7

Antibody identification, 11 cell panel

Lorne, UK

RT, 37 0C, LISS Additive

1+ at 370C with all cells
and 4+ agglutination with
all cells in both IAT’’s

8

Kell phenotype

DiaMed-ID antigen

Micro column

profile Dia-Med AG,

gel technique with

Switzerland

appropriate controls

K-, k+

Table 2. Confirmatory serologic tests.
S. No

Test

Reagent

Result

Result

1.

Reaction with Rh Null cells

-

-

No agglutination

2.

Rh phenotype of red cells

DIA Med ID II

No agglutination with

D-- phenotype

3.

Chemiluminescence test (CLT)

-

a.

Prediction of transfusion outcome: Red Cell

anti C, c, E, e
-

-

Opsonic index without

Opsonic index With AB serum

AB serum

b.

Prediction of HDFN Red cell

R1 w R1

17.6

29.4

Rh Null

1.2

1.2

-

-

CLT %

R1 w R1
Rh Null

176
-

2

HDFN: Haemolytic disease of fetus and newborn

needed which were not available with us therefore the
patient's blood samples were sent to International Blood
Group Reference Laboratories (IBGRL), Bristol, UK.
Meanwhile search for compatible blood among first-degree
relatives was made and yielded no success.
Erythropoietin at a dose of 40 µg/kg/day was started
in addition to other antianaemics and haemoglobin was
successfully raised to 10.5 g/dl. One autologous unit of 300
ml was collected preoperatively. Because of scar tenderness
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and distressing dyspnoea due to hydramnios caesarean
section was performed, three days after autologous donation
on 25 May 2003, delivering dead hydropic foetus. Tubal
ligation was not performed. Autologous unit was transfused
in postoperative period and the patient made uneventful
recovery.
Results from IBGRL were received 10 days after her
operation, which are shown in Table 2. The rare
alloantibody in proposita was antiRh17, which was further
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confirmed by phenotyping patient's red cells at our center.
There were no C/c and E/e antigens on her cells (Table 3,
Figure). The opsonic index in chemiluminescence test show
significant transfusion and haemolytic disease causing
potential of the antibody. Later Rh phenotyping of patient's
family was done, whose results are shown in Table 3 and
Figure 1. Both parent's RBC phenotype was B, D+,C+,e+
and their most likely genotypes were DCe/D-- . The
proposita and her sister were D--/D--. None of the family
members was Rh Null. The patient and her husband were
counselled in detail. Patient and her sister having regular
follow-up at our institution.

Discussion
The proposita developed an unusual alloantibody,
anti Rh 17, as a result of a transfusion in her second post
partum period. This antibody has reactivity against Rh17
(Hro) antigen of Rh blood group system and is formed by
individuals who lack all Rh antigens (C/c and E/e antigen
therefore have no Hro antigen) except D1. Genetically Rh
antigens are coded by 2 genes on chromosome 1. RHD
coding for D antigen and RHCE is responsible for C/c and
E/e antigens. 4 Molecular basis for D-- phenotype is not clear
but recombination of RHD and RHCE genes have been
documented. 5 This antibody is formed by immune stimulus6
like transfusion or pregnancy and usually show single
specificity but sometimes separate specificities like anti 'e'
may be seen.7 Our patient escaped immunization due to
fetomaternal haemorrhage during her first two pregnancies
hence she was able to have an alive and normal baby after
the second pregnancy. Immune causes of hydrops foetalis
were not excluded after birth of first hydropic baby (third
pregnancy) although it required a simple test like antibody
screening with standard reagents. Anti Rh 'D' is the most
common alloantibody causing morbidity and mortality due
to HDN 8 followed by anti c, Kell, C, E, e, Duffy and Kidd.9
These must be excluded especially with a history of
hydropic baby, irrespective of the Rh blood group.
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Determining specificity of antibody is important for future
obstetrical management. Therefore all efforts should be
made to achieve this.
Initial red cell serological tests and their results are
shown in Table 1. These indicated that either patient has
clinically significant, pan reactive, IgG alloantibody, against
some public antigen or an autoantibody, which is capable of
crossing the placenta and causing foetal complications.
Negative direct antiglobulin and auto control test excluded
the possibility of auto antibodies and also these are rarely
associated with hydrops. Other alloantibodies likely to yield
similar results with the red cell identification panel used
were anti Tja, anti U, and anti 'k' (chelano) antibody. Anti
chelano was excluded indirectly by phenotyping patient's
cells for 'k' antigen, on the basis that if the cells were 'k'
antigen positive then antibody could not be 'anti k'. In the
absence of appropriate reagents we could not exclude other
suspected antibodies and did not consider Rh system
antibodies, as the red cell panel in use was adequate to
exclude common anti Rh antibodies. Diagnosis of
specificity of antibodies against high frequency, public
antigens is important for future counseling, obstetrical
outcome, neonatal management and arranging transfusion
support. Help from a reference center abroad (International
Blood Group Reference Laboratories (IBGRL), Bristol UK)
was sought and patient's serum samples were sent to them.
In the absence of inventory or database for rare donors in
any local blood bank it was almost impossible to find
compatible blood. We resorted to time old method of
checking first-degree relatives of patient for compatible
phenotype. None of those brought to us had compatible
blood although later family studies did reveal that one sister
(fifteen years old) had exactly the same phenotype as
proposita (Table 3). There is no national frozen blood bank
of rare donors either which could have provided rare
phenotype red cells as is usually possible in many
developed countries.
Phenotyping of red cells was done at our center as
the cells were haemolyzed during transportation, which
revealed absence of C/c and E/e antigens on patient's red
cells (Table 2). IBGRL, Bristol UK communicated to us that
this phenotype is most prevalent in Japanese population and
the frozen blood banks there can provide such blood on
request. Also we were provided important contacts in Japan.
The results of Chemiluminescence test (CLT) done at
IBGRL yielded expected results because the past or present
history of hydrops is the most sensitive indicator of clinical
significance of any alloantibody (Table 2).
Elective Caesarian section had to be done without
delay to avoid complications of the dead baby and also
worsening polyhydramnios was causing tenderness in
previous surgical scar and respiratory distress to the patient.
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This precluded liaison with Japanese blood banks, which we
were contemplating. Meanwhile small volume autologous
donation was collected as patient's haemoglobin had risen
adequately within one week with antianaemics and
erythropoietin. Autologous donation in the form of
predeposit, preoperative haemodilution or cell salvage are
very important means of providing blood for cases with rare
alloantibodies and limited resources. 10 It can prove to be a
safe option even with co-morbid conditions provided
haemoglobin is adequate and blood is collected carefully.
This can be done as small volume frequent donations. Tubal
ligation was not performed at the time of caesarian section
and we are unaware of any contraceptive counselling of the
couple, therefore we assume tht they may be at risk for
future foetal complications.
People have tried to lower the alloantibody levels in
post conception period with plasma exchange 11 without
much success therefore such efforts may not help our
patient in future. Very few similar cases due to anti Rh17
antibodies have been reported. 12-15 Usually this antibody
causes moderate to severe haemolytic disease of the
newborn. The foetal management includes intrauterine
transfusions with frozen rare donor blood or maternal blood
if diagnosed early during pregnancy.13 In other cases
exchange transfusions with maternal blood (frozen
previously or freshly donated) has been used with
successful outcome.16 Some authors have reported good
neonatal outcome even with repeated incompatible Rh D
negative exchange transfusions. 17,18 Use of intravenous
immunoglobulins to inhibit haemolysis before and
following the exchange transfusion has been reported to be
successful.15,19
The extensive family studies of proposita were
undertaken (Table 3 and Figure) with an aim of finding
more compatible donors for future as well as for sending
blood of those affected to New York blood center, USA, for
identification of mutation in the family which may be a new
one, not previously reported. Also these individuals can
help us to prepare rare red cell reagent panels that are
expensive if imported and has short shelf life. These
individuals can also become part of rare donors programme
in future. Our center is now better prepared to arrange blood
for the patient or her foetus in case of intrauterine
transfusion, in future. The options are to get blood donation
from her sister, autologous donation and/or frozen blood
requested from abroad.
We gained useful insight that excluding antibodies in
Rh blood group systems before considering any other
specificity is the most useful practical approach in case of
anti IgG alloantibodies in pregnant ladies. In absence of rare
red cell panels, phenotyping for Rh blood group system
using basic sera or micro column gel system could help to
exclude a significant group of alloantibodies, although this
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is a deviation from traditional teaching and can not be
applied to recently transfused patients. Antibody screening
of all pregnant ladies, irrespective of Rh group should be
carried out as per standard guidelines for serological
screening tests in pregnancy.20 This is particularly indicated
after birth of a hydropic baby. Maintaining rare red cells
reagents may not be possible for every transfusion center,
however liaison with international reference centers can
have fruitful results.
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